ANI Pharmaceuticals Third Quarter 2024 Earnings: Revenues Beat Expectations, EPS Lags
Revenue exceeded analyst estimates by 2.7%. Earnings per share (EPS) missed analyst estimates significantly. Looking ahead, revenue is forecast to grow 8.8% p.a. on average during the next 3 years, compared to a 10% growth forecast for the Pharmaceuticals industry in the US. Performance of the American Pharmaceuticals industry.
ANI Pharmaceuticals, Inc. (NASDAQ:ANIP) Q3 2024 Earnings Call Transcript
Q3 2024 Earnings Call Transcript November 8, 2024 ANI Pharmaceuticals, Inc. beats earnings expectations. Reported EPS is $1.34, expectations were $1.09. Operator: Good day, everyone, and welcome to today’s ANI Pharmaceuticals Inc Third Quarter 2024 Earnings Results Call.
ANI Pharmaceuticals Q3 2024 Earnings Preview
ANI Pharmaceuticals (NASDAQ:ANIP) is scheduled to announce Q3 earnings results on Friday, November 8th, before market open. The consensus EPS Estimate is $1.09 (-14.2% Y/Y) and the consensus Revenue Estimate is $144.
ANI Pharmaceuticals reports Q3 adjusted EPS $1.34, consensus $1.09
Reports Q3 revenue $148.3M, consensus $144.35M. “I am very pleased to report our third quarter results as we continue to execute against
ANI Pharmaceuticals (ANIP) Q3 Earnings and Revenues Surpass Estimates
ANI Pharmaceuticals (ANIP) came out with quarterly earnings of $1.34 per share, beating the Zacks Consensus Estimate of $1.09 per share. This compares to earnings of $1.27 per share a year ago. These figures are adjusted for non-recurring items.
ANI Pharmaceuticals: Buy Rating Backed by Consistent Revenue Growth, Strategic Acquisitions, and Strong Market Position
ANI Pharmaceuticals (ANIP – Research Report), the Healthcare sector company, was revisited by a Wall Street analyst today. Analyst Oren ...
ANI Pharmaceuticals Is Acting Like It Is Being Acquired
ANIP may be acquired soon with a potential offer exceeding $8 billion and contingent on FDA approval of a new drug filed in ...
A Peek at ANI Pharmaceuticals's Future Earnings
ANI Pharmaceuticals ranks in the middle for consensus rating among its peers. It is at the bottom for revenue growth. In terms of gross profit, it is at the top among its peers. However, for return on ...
Business Insider55m
Truist Financial Remains a Hold on ANI Pharmaceuticals (ANIP)
Truist Financial analyst Les Sulewski maintained a Hold rating on ANI Pharmaceuticals (ANIP – Research Report) today and set a price target of $62.00. The company’s shares closed last Friday at ...
Yahoo Finance6d
ANI Pharmaceuticals to Present at Guggenheim's Inaugural Healthcare Innovation Conference and Jefferies London Healthcare Conference in November
The replay of the webcast will be accessible for 90 days. About ANI Pharmaceuticals, Inc. ANI Pharmaceuticals, Inc. (Nasdaq: ANIP) is a diversified biopharmaceutical company committed to its ...
ANI: Q3 Earnings Snapshot
BAUDETTE, Minn. (AP) — BAUDETTE, Minn. (AP) — ANI Pharmaceuticals Inc. (ANIP) on Friday reported a third-quarter loss of $24.2 million, after reporting a profit in the same period a year earlier. The ...